Therapeutic Asset Ratings

166 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Benserazide Parkinson Disease	Ankara Ataturk Sanatorium Training and Research Hospital	P4	BBB (76)
Ongentys Parkinson Disease	Bial - Portela C S.A.	P4	BBB (76)
LEVODOPA Parkinson Disease	McMaster University	P4	BBB (72)
ipx203 Parkinson Disease	The Cleveland Clinic	P4	BB (69)
Terazosin Parkinson Disease	Nandakumar Narayanan	P4	BB (68)
Droxidopa Parkinson Disease	Loma Linda University	P4	BB (66)
Ambroxol Parkinson Disease	University College, London	P3	BB (65)
Tavapadon Parkinson Disease	Cerevel Therapeutics, LLC	P3	BB (65)
Amantadine Parkinson Disease	University Hospital, Toulouse	P4	B (63)
HYPOXANTHINE RIBOSIDE Parkinson Disease	Fujita Health University	P3	B (63)
Paroxetine Parkinson Disease	State University of New York at Buffalo	P3	B (63)
Posiphen Parkinson Disease	Annovis Bio Inc.	P3	B (63)
APOMORPHINUM Parkinson Disease	Alexza Pharmaceuticals, Inc.	P2	B (62)
Acetylsalicylic Acid Parkinson Disease	InSightec	P4	B (61)
Dipyridamole Parkinson Disease	InSightec	P4	B (61)
MELATONIN Parkinson Disease	Bangladesh Medical University	P4	B (61)
Mirabegron Parkinson Disease	VA Office of Research and Development	P4	B (61)
Plavix Parkinson Disease	InSightec	P4	B (61)
Acp-103 Parkinson Disease	Joshua Woolley, MD, PhD	P4	B (60)
cvn424 Parkinson Disease	Cerevance	P3	B (60)
FDOPA Parkinson Disease	Andrew Newberg	P3	B (59)
Dapagliflozin Parkinson Disease	Mayo Clinic	P4	B (58)
Safinamide Mesilate Parkinson Disease	Eisai Korea Inc.	P4	B (58)
Sitagliptin Parkinson Disease	Mayo Clinic	P4	B (58)
Letrozole Parkinson Disease	Tanta University	P3	B (58)

Showing 1 to 25 of 166 assets

PreviousPage 1 of 7Next